EDNRA and pulmonary arterial hypertension: Sitaxentan (Table 1; Thelin, TBC11251) (Wu et al., 1997; Barst et al., 2007) was introduced in 2008 as a potent, competitive, long-acting, orally active ETA antagonist, the most highly selective to be approved for the treatment of PAH.